Little Green PharmaASX:LGP PB Ratio is 0.24 as of Jun. 26, 2026, which is 56% below its 10-year median of 0.54. The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Little Green Pharma ranks better than 98.05% on this metric.
Little Green Pharma Ltd stock PB Ratio (=0.28) is close to 10-year low of 0.28.
The historical rank and industry rank for Little Green Pharma's PB Ratio or its related term are showing as below:
ASX:LGP'
s PB Ratio Range Over the Past 10 Years
Min: 0.23 Med: 0.54 Max: 10.16
Current: 0.23
During the past 7 years, Little Green Pharma's highest PB Ratio was 10.16. The lowest was 0.23. And the median was 0.54.
ASX:LGP's PB Ratio is ranked better than 98.05% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs ASX:LGP: 0.23
During the past 12 months, Little Green Pharma's average Book Value Per Share Growth Rate was -3.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -0.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.90% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Little Green Pharma was 40.80% per year. The lowest was -11.50% per year. And the median was 18.70% per year.
Back to Basics: PB Ratio
Little Green Pharma (ASX:LGP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Little Green Pharma PB Ratio Related Terms
Little Green Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Little Green Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Little Green Pharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Little Green Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Little Green Pharma (ASX:LGP) has a PB Ratio of 0.24 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Little Green Pharma and its competitors. This is 56% below median its historical median of 0.54. Over the past decade, Little Green Pharma's PB Ratio has ranged from 0.23 to 10.16. According to the industry distribution chart, Little Green Pharma ranks #18 out of 922 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is Little Green Pharma's PB Ratio too high?
Little Green Pharma's current PB Ratio of 0.24 is 56% below median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 10.16. The Drug Manufacturers industry median PB Ratio is 1.83. Little Green Pharma's value of 0.24 is 86.8% below this industry median. Based on the distribution chart, Little Green Pharma ranks #18 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Little Green Pharma's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Little Green Pharma ranks #18 out of 922 companies for PB Ratio. This places Little Green Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.83. Little Green Pharma's value of 0.24 is 86.8% below this benchmark. Historically, Little Green Pharma's own PB Ratio has ranged from 0.23 to 10.16 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 1.83, Little Green Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Little Green Pharma's current PB Ratio of 0.24 is 86.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Little Green Pharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Little Green Pharma's current PB Ratio is 0.24, which is 56% below median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.17, compared to a current price of A$0.06 — trading 62.4% below its estimated fair value. The current PB Ratio is 0.24, which is 56% below median its 10-year median of 0.54 and 86.8% below the Drug Manufacturers industry median of 1.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current PB Ratio is 0.24 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LGP has been successfully added to your 